Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + pomalidomide + dexamethasone versus elotuzumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
NL-OMON56661Phase 3Recruiting
- Sponsor
- Stichting European Myeloma Network (EMN)
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selinexor, elotuzumab, pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Stichting European Myeloma Network (EMN). Primary endpoint: Progression-free survival. Started Jan 2024; status: recruiting.
02
Drugs
selinexorelotuzumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56661.